Parkinson's Program · In-Depth

The evidence, the team, and the journeys behind Parkinson's restoration

A closer look at the science of intensive neurorehabilitation and medication optimization, illustrative patient outcomes, the movement-disorder specialists involved, and how a program cycle is structured.

Clinical Evidence

What the evidence describes

Cuba's Parkinson's program combines intensive therapy with careful medication management and biotechnology. These summaries outline the scientific basis — individual outcomes vary.

Intensive neurorehabilitation in Parkinson's

High-volume, multidisciplinary therapy (4–6 hours daily across physical, occupational, and speech therapy) is associated with gains in motor scales such as the UPDRS and in functional independence measures.

CIREN outcome reports; movement-disorder rehabilitation literature.

Medication optimization

Careful titration of dopaminergic therapy — timing, formulation, and dose — can reduce motor fluctuations and dyskinesia while maximizing 'on' time, especially under specialist supervision.

International Parkinson's treatment guidelines.

Neuroprotective biotechnology

Cuban biotech options, including NeuralCIM® (NeuroEPO), are under study for potential disease-modifying effects aimed at slowing neuronal loss — administered under medical monitoring.

Center of Molecular Immunology (CIM), Havana.

Non-motor symptom care

Addressing depression, sleep disruption, and cognitive change — not only tremor and rigidity — is linked to better quality of life for both patients and caregivers.

Parkinson's non-motor symptom consensus.

Educational summary only. Treatment eligibility is determined by specialist review of each patient's records. Outcomes vary and are not guaranteed.

Case Studies

Illustrative patient journeys

Composite cases reflecting typical patient profiles and reported experiences. Names and details have been changed to protect privacy.

"I hadn't walked without freezing for two years. After three weeks of daily therapy I crossed my living room without stopping. My wife cried."

J. Martínez, 61

Parkinson's, Hoehn & Yahr stage 2

Reduced tremor; improved gait after 4-week cycle

"The pharmacist sat with me for an hour and rebuilt my medication schedule. The difference in my good hours was immediate — and they taught my US doctor why."

P. Carter, 58

Parkinson's with motor fluctuations

Smoother 'on' time after medication tuning

"I was afraid to leave the house. The balance training gave me back my independence — and the remote check-ins kept me honest once I was home."

H. Castillo, 67

Parkinson's, postural instability

Fewer falls; restored confidence in walking

Composite illustrative cases based on typical patient profiles. Names and details have been changed to protect privacy. Individual results vary.

Specialist Team

The movement-disorder team

A coordinated team of movement-disorder neurologists, therapists, and a clinical pharmacist — working under one plan, not in separate silos.

Dr. A. Ramírez

Movement-Disorder Neurologist

Diagnoses, stages (UPDRS), and directs the personalized plan — the clinical lead for each Parkinson's patient.

Lic. M. Torres

Physical Therapist

Delivers intensive daily gait, balance, and strength training to restore functional mobility and reduce fall risk.

Lic. F. Núñez

Occupational Therapist

Retrains fine motor control and daily-living skills to preserve independence at home.

Dr. L. Herrera

Clinical Pharmacist

Tunes levodopa and dopaminergic therapy to maximize benefit and minimize dyskinesia and side effects.

Lic. S. Mendoza

Speech-Language Therapist

Addresses hypophonia, articulation, and swallowing difficulties common in Parkinson's.

Dr. E. Vargas

Neuropsychologist

Supports the cognitive and emotional changes — depression, anxiety, executive change — that accompany the disease.

Program Structure & Investment

Program structure & investment

Every plan is individualized after specialist review. These tiers describe typical pathways — final scope and cost are confirmed after records evaluation.

Remote Opinion

Records review · 48 hours

No charge

  • Review of US records & MRI
  • Movement-disorder specialist summary
  • Medication review
  • Telehealth consultation option

Standard Cycle

4 weeks on-site

Core program

  • Week 1 neurological & UPDRS assessment
  • 3 weeks intensive daily therapy
  • Medication optimization
  • Structured discharge & home plan

Extended Cycle

6–8 weeks on-site

Intensive track

  • Extended intensive therapy (4–6 h/day)
  • Neuroprotective therapy options
  • Re-testing & progress measurement
  • Coordinated remote follow-up

Pricing varies with clinical complexity, program length, and required services. A written estimate is provided after the free remote records review. NeuroCuba does not guarantee specific outcomes, and all treatment is subject to specialist approval.

Ready to go deeper?

Submit medical records for a free remote review, or speak with an international care coordinator about the Parkinson's program.

AI ChatWhatsApp